Lidocaína Accord

Lidocaine, the active ingredient in Lidocaína Accord, is a local anesthetic (amide type) presented as a sterile injectable solution for epidural, intramuscular and intravenous use. It provides reversible nerve block for minor surgical procedures, epidural analgesia, intravenous regional anesthesia and intramuscular pain control in adult patients. GNH USA supplies Lidocaína Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lidocaine is a local anesthetic used to provide reversible nerve block for various procedural and pain‑management applications. - Minor surgical procedures: delivers local anesthesia to enable pain‑free surgery. - Epidural analgesia: produces segmental analgesia for labor or postoperative pain control. - Intravenous regional anesthesia (Bier block): creates regional anesthesia of a limb for short procedures. - Intramuscular infiltration for pain control: reduces localized musculoskeletal pain during interventions.

Lidocaine may cause a range of adverse reactions, from mild to severe, depending on dose and patient factors.

Common Side Effects: - Tingling or numbness at the injection site - Mild hypotension or dizziness - Nausea or metallic taste - Transient visual disturbances - Localized swelling or erythema - Headache

Serious or Rare Side Effects: - Methemoglobinemia - Seizures or convulsions - Cardiac arrhythmias, including ventricular tachycardia - Severe allergic reactions (anaphylaxis) - Respiratory depression or apnea - Systemic toxicity leading to central nervous system depression

When using Lidocaína Accord, clinicians should observe several safety measures. - Cardiac assessment: evaluate patients with known heart disease before administration. - Hepatic function: use caution in patients with liver impairment as metabolism may be reduced. - Dose limitation: avoid exceeding recommended maximum doses to prevent systemic toxicity. - Elderly patients: consider lower initial doses due to altered pharmacokinetics. - Concomitant CNS depressants: monitor for additive effects. - Store at ambient temperature: keep in original container, protect from moisture and light.

Lidocaine can interact with other medicines, altering its plasma concentration or enhancing toxicity.

Major Interactions (Avoid): - Class I antiarrhythmics (e.g., quinidine) – may increase cardiac toxicity. - Amiodarone – can raise lidocaine levels, risking systemic effects. - Cimetidine or erythromycin – inhibit hepatic metabolism, leading to higher concentrations.

Moderate Interactions (Monitor Closely): - Beta‑blockers – may potentiate bradycardia. - Calcium channel blockers – can enhance negative inotropic effects. - CNS depressants (e.g., benzodiazepines, opioids) – increase risk of respiratory depression.